Lytix Biopharma AS (OSL: LYTIX)
Norway
· Delayed Price · Currency is NOK 5.74
-0.02 (-0.35%)
Jan 17, 2025, 4:03 PM CET
Lytix Biopharma AS Company Description
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.
Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials.
The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.
Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
Lytix Biopharma AS
| Country | Norway |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Oystein Rekdal |
Contact Details
Address: Sandakerveien 138 Oslo, 0484 Norway | |
| Website | lytixbiopharma.com |
Stock Details
| Ticker Symbol | LYTIX |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010405780 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oystein Rekdal Ph.D. | Co-Founder and Chief Executive Officer |
| Gjest Breistein M.Sc. | Chief Financial Officer |